90 related articles for article (PubMed ID: 11698228)
1. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.
Walli RK; Michl GM; Bogner JR; Goebel FD
Eur J Med Res; 2001 Oct; 6(10):413-21. PubMed ID: 11698228
[TBL] [Abstract][Full Text] [Related]
2. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
3. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
[TBL] [Abstract][Full Text] [Related]
4. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
5. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
Martínez E; Conget I; Lozano L; Casamitjana R; Gatell JM
AIDS; 1999 May; 13(7):805-10. PubMed ID: 10357379
[TBL] [Abstract][Full Text] [Related]
6. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
7. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
8. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
[TBL] [Abstract][Full Text] [Related]
9. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
11. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
12. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
13. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
14. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.
Petit JM; Duong M; Duvillard L; Piroth L; Grappin M; Verges B; Chavanet P; Brun JM; Portier H
Horm Metab Res; 2000 Sep; 32(9):367-72. PubMed ID: 11014386
[TBL] [Abstract][Full Text] [Related]
16. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.
Jordan J; Cahn P; Goebel F; Matheron S; Bradley C; Woodcock A
AIDS Patient Care STDS; 2005 Jan; 19(1):9-18. PubMed ID: 15665631
[TBL] [Abstract][Full Text] [Related]
17. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
18. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
[TBL] [Abstract][Full Text] [Related]
19. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Fisac C; Fumero E; Crespo M; Roson B; Ferrer E; Virgili N; Ribera E; Gatell JM; Podzamczer D
AIDS; 2005 Jun; 19(9):917-25. PubMed ID: 15905672
[TBL] [Abstract][Full Text] [Related]
20. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
